ArticleEuropean journal of medical research2025
Deep learning-based predictive models for assessing the impact of clinical factors and second primary malignancy on survival in patients with colorectal cancer.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ten-Year Outcomes in Colorectal Cancer-Competing Risks and Patient Vulnerability: A Prospective Multicenter Observational Study.Journal of clinical medicine · 2026Article
- mRNA vaccine development for tuberculosis: antigen design, immune mechanisms, and translational challenges.Archives of microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we first utilized a data set of 21,522 patients with colorectal cancer (CRC) with a second primary malignancy (SPM) to develop a deep learning model for predicting 1-year, 3-year, and 5-year survival outcomes in patients with CRC who subsequently developed SPM. Our models demonstrated high performance, achieving area under the curve (AUC) values of 0.850 (95% confidence interval [CI] 0.840-0.861), 0.856 (95% CI 0.850-0.861), and 0.848 (95% CI 0.843-0.853) for the 1-year, 3-year, and 5-year survival predictions, respectively. We then examined the impact of 33 clinical factors on these predictions and found that age, radiation therapy for the SPM, and sex were the most influential factors. Age and metastatic status of the SPM emerged as the most critical predictors. Finally, using one-hot encoding, we evaluated the effects of various SPMs on survival outcomes in patients with CRC and provided clinical interpretations of these findings. Our analysis indicated that patients with second primary prostate cancer and CRC generally have better survival prospects than that of those with other SPMs. Patients with second primary pancreatic and gastric cancers have poor survival outcomes. These findings provide valuable insights into the intricate interactions among CRC, SPM, and various clinical factors, thereby improving the treatment and evaluation of patients with CRC and SPM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.